Time	Monday 29th Oct	Tuesday 30th Oct	Wednesday 31st Oct	Thursday 1st Nov	Friday 2nd Nov
8:00 AM			Registration		
8:45 AM	**Opening session: Dr. Kalet León (Cuba)**	*Session: Deciphering immune-regulatory circuits, which impair the efficacy of current immune-therapies, in tumors microenvironments*	*Session: Design of novel cancer vaccines and adoptive cell therapies as strategies to increase the number of non-exhausted immune effector cells in tumor*	*Session: Protein engineering approaches to get better anti-cancer weapons*	*Session: Translational clinical research to dissect the mechanism of action and of acquired resistance to current immunotherapies of cancer*
9:00 AM		**Dr. Jerome Galon (France)**: Immune contexture in the era of cancer immunotherapy	**Dr. Jason Lohmueller (USA)**: Vaccines for preventon of non-viral cancers	**Dr. Andrew Bradbury (USA)**: The impact of Next Generation Sequencing on antibody library generation and selection	**Ms. Elaine Scheye (USA)**: Eradicating "The Emperor of All Maladies," Cancer
9:30 AM	*Session: Decrypting the tumor biology to design more effective treatments* **Dr. Kelvin Lee (USA)**: CD28-mediated regulation of multiple myeloma cell proliferation and survival	**Dr. Kelly Singel (USA)**: Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment via complement C3 activation	**Dr. Aaron Miller (USA)**: A HLA-agnostic functional neoantigen discovery platform	**Dr. Jacob Glanville (USA)**: Bruteforcing Immune Oncology Discovery with Computational Immuno-Engineering	**Dr. Mary Reid (USA)**: A role for vaccines in cancer prevention
10:00 AM	**Dr. Shivana Lightman (USA)**: A new role for Indoleamine 2,3-dioxygenase (IDO): supporting the survival of bone marrow resident long lived plasma cells (LLPC)	**MSc. Liliana Oliver (CUBA)**: VSSP promotes an IRF8-driven bias to monocytic over granulocytic lineage and disrupt the G-CSF mediated induction of PMN-MDSC	**Dr. Giuseppina Barutello (Italy)**: Maternal immunization against ALK hinders tumor progression in neuroblastoma-prone offspring	**Prof. Ronald Geyer (Canada)**: Post-translational antibody engineering	**Dr. Yasmin Thanavala (USA)**: Augmentation of IFN-γ$^+$ CD8$^+$ T cell responses following therapy correlates with survival of patients with advance hepatocellular carcinoma
10:30 AM	**Dr. Adam Utley (USA)**: CD28 induces metabolic fitness in multiple myeloma for ROS-dependent survival	**Dr. Colin Chavel (USA)**: Protein kinase C driven dendritic cell differentiation	**Dr. Federica Riccardo (Italy)**: Anti-CSPG4 DNA vaccinationfor the treatment of malignant melanoma: a comparative oncology trial for translational medicine	**Dr. Deborah Charych (USA)**: Harnessing potent cytokine agonist pathways by kinetic engineering	**Dr. Andrea Alimonti (Switzerland)**: IL23 secreted by myeloid cells drives castration resistant prostate cancer
11:00 AM			Coffee break		
11:30 AM	**Prof. Yosef Yarden (Israel)**: Oligoclonal combinations ofantibodies overcome resistnae to third-generation EGFR kinase inhibitors	**Prof. Paul Neeson (Australia)**: Increased and co-localized CD4+FOXP3+ and CD8+ T cells is a strong independent prognostic indicator in gastric cancer	**Dr. Pravin Kaumaya (USA)**: HER-2 B cell epitope peptide-based cancer vaccines and combination immunotherapies with EGFR, HER-3, IGF-1R, VEGF and a therapeutic vaccine of PD-1.	**Dr. Gertudis Rojas (CUBA)**: Engineering phage-displayed Interleukin-2 for better developability: directed evolution of highly soluble super-secreted variants	**Dr. Mónica Bécquet (CUBA)**: HEBERSaVax: beyond VEGF specific humoral response induction
12:00 PM	**Dr. William D. Cress (USA)**: STK11 pathway disruption alters metabolism and immune surveillance in lung adenocarcinoma	**Dr. Tali Feferman (Israel)**: Oxygen deprivation during T cell priming enhances their cytolysis and improves their anti-tumor function in a mouse melanoma model	**Dr. Jason Muhitch (USA)**: It takes two to tango: targeting Dendritic cell-mediated T cell activation and tumor-intrinsic barriers towards effective management of renal cell carcinoma	**Dr. Angelica Medina-Cucurella (USA)**: Developing novel protein engineering platforms to enable specificity engineering and epitope mapping of therapeutic monoclonal antibodies	**Dr. Danay Saavedra (CUBA)**: Reversing T cell immunosenescence for the improvement of immunotherapeutic potential
12:30 PM	**MSc. Gretchen Bergado (Cuba)**: Impact of HER1 and HER2 downregulation induced by polyclonal antibodies on tumor cells hallmarks: influence of activating mutations	**Prof. Andrea Facciabene (USA)**: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12	**Prof. Daniel Speiser (Switzerland)**: Tumor cell-intrinsic and -extrinsic immune escape mechanisms. Melanocytes and epithelial cells are also "immune cells"	**Prof. Michael Birnbaum (USA)**: An unbiased determination of pMHC repertoires for improved antigen prediction	**Dr. Robert Rottapel (Canada)**: Identification of Relaxin mediated autocrine loop required for high grade ovarian cancer tumor growth and cisplatin resistance
1:00 PM	**Dr. John McCafferty (UK)**: Affinity maturation of a PD1 blocking antibody using large mammalian display libraries created by gene editing				
1:30 PM			*Lunch (1:00-2-30pm)*		
2:00 PM					
2:30 PM	*Welcome Lunch (1:30-3:30pm)*	*Group photo IT2018*	**Prof. Michael Milone (USA)**: Improving cancer immunotherapy through immunoreceptor engineering	**Dr. Kyle Barlow (USA)**: Flex ΔΔG: Incorporating backbone flexibility into computational models of antibody-protein interfaces improves prediction of change in binding free energy upon mutation	**Dr. Saar Gill (USA)**: Chimeric antigen receptor T cell therapy of myeloid malignancies
3:00 PM		**Prof. Stephan von Gunter (Switzerland)**: Tumor surface glycosylation: biological implications and opportunities	**Prof. Phil Darcy (Australia)**: Targeting tumor induced immunosuppression for enhancing CAR T cell therapy	**Prof. Itar Benhar (Israel)**: A modular platform for targeted RNAi therapeutics using biologically-lipidated antibodies	**Dr. Renier Brentjens (USA)**: CARs and Armored CARs
3:30 PM		**Dr. Bonnie Hylander (USA)**: The role of chronic stress and adrenergic signaling in cancer progression	**Dr. Josée Golay (Italy)**: A flexible therapeutic strategy for leukemia using ex-vivo expanded T cells combined with bispecific antibodies	**Prof. Stephen Michnick (Canada)**: Modulation of cell surface antigen expression by modulation of protein phae-separation	**Prof. Bruce Levine (USA)**: Development andtranslation of chimeric antigen receptor T cells: from boutique to global
4:00 PM	*Visit to CIM (3:30-6:30pm)*	**Dr. Thomas Rothstein (USA)**: Immune Suppression Through CD73 Expression and Adenosine Production	**MSc. Magela Montalvo (CUBA)**: To be defined	**Dr. Lafita Zekri (Germany)**: Novel optimized antibody formats for cancer therapy	*Coffee break*
4:30 PM			Coffee break		
5:00 PM		**Dr. Henning Walczak (UK)**: TNF- and TRAIL-induced signalling in cell death, inflammation and immunity in cancer	Poster Session (1h30min)		**Closing session**
5:30 PM		**Prof. Denis Thieffry (France)**: Synergy between T cell receptor and Toll-like receptor 5 signaling for CD4+ T cell activation		*Old Havana tour+Dinner at "La imprenta" Restaurant*	
6:00 PM		Poster Session (1h)	*Cultural activity [Classical Ballet] at "The National Theater"*		*Farewell party at "Cabaret Turquino" (7:00-9:30pm)*
6:30 PM					